Search

Author/Creator Califano, C.

2. DOSE DENSE ABVD (DD‐ABVD) AS FIRST LINE THERAPY IN EARLY‐STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI. (12th June 2019)

Authors:
Mazza, R.; Spina, M.; Califano, C.; Gaudio, F.; Carella, M.; Consoli, U.; Palombi, F.; Musso, M.; Pulsoni, A.; Kovalchuk, S.; Bonfichi, M.; Ricci, F.; Fabbri, A.; Liberati, A.; Rodari, M.; Giordano, L.; Balzarotti, M.; Gallamini, A.; Ricardi, U.; Chauvie, S.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
291
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL. (23rd June 2022)

Authors:
Ladetto, M.; Tavarozzi, R.; Evangelista, A.; Zanni, M.; Tucci, A.; Anastasia, A.; Botto, B.; Boccomini, C.; Bolis, S.; Volpetti, S.; Zilioli, V. R.; Puccini, B.; Arcari, A.; Pavone, V.; Gaidano, G.; Corradini, P.; Tani, M.; Ferrero, S.; Cavallo, F.; Milone, G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1032
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS. (23rd June 2022)

Authors:
Bruzzese, A.; Derudas, D.; Galli, M.; Martino, E. A.; Rocco, S.; Conticello, C.; Califano, C.; Giuliani, N.; Mangicavalli, S.; Farina, G.; Lombardo, A.; Brunori, M.; Rossi, E.; Antonioli, E.; Ria, R.; Zambello, R.; Di Renzo, N.; Mele, G.; Marcacci, G.; Pietrantuono, G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1856
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. PB1995: SAFETY OF SUBCUTANEOUS DARATUMUMAB IN MULTIPLE MYELOMA: A RETROSPECTIVE MULTI-CENTER REAL LIFE EXPERIENCE. (23rd June 2022)

Authors:
De Novellis, D.; Carobene, A.; Fontana, R.; Mettivier, L.; Trastulli, F.; Rocco, S.; Palmieri, S.; Di Perna, M.; Pagano, A.; Giudice, V.; Califano, C.; Ferrara, F.; Selleri, C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1866
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38). (17th June 2021)

Authors:
Pirosa, M. C.; Orsucci, L.; Feugier, P.; Tani, M.; Ghesquieres, Hervé; Musuraca, G.; Baldini, L.; Merli, F.; De Renzis, B.; Gyan, E.; Gini, G.; Marino, D.; Gressin, R.; Morschhauser, F.; Palombi, F.; Cavallo, F.; Conconi, A.; Le Gouill, S.; Tilly, Hervé; Zanni, M.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. S221: BORTEZOMIB TO R-DHAP COMPARED TO R-DHAP IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE TO STEM CELL TRANPLANTATION: FINAL RESULTS OF PHASE II RANDOMIZED FIL-VERAL12. (23rd June 2022)

Authors:
Chiappella, A.; Balzarotti, M.; Botto, B; Castiglione, A.; Cavallo, F.; Usai, S. V.; Zanni, M.; Califano, C.; Re, F.; Ghiggi, C.; Olivieri, A.; Corradini, P.; Liberati, A. M.; Volpetti, S.; Michieli, M. G.; Tucci, A; Gaidano, G.; Tani, M.; Ciambelli, F.; Musuraca, G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
122
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗